泰恩康 reported revenue of ¥0.32B for the period ended 2026-06-30, -7.7% year on year. Net income was ¥-0.00B, a -1.2% net margin on a 56.1% gross margin. The largest revenue line is 眼科用药 at 28% of the total. Free cash flow for the period was ¥0.04B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.32B | -7.7% |
| Gross profit | ¥0.18B | — |
| Operating income | ¥-0.02B | — |
| Net income | ¥-0.00B | -112.5% |
| Gross margin | 56.1% | Net margin -1.2% |
| Revenue Q/Q | -31.0% | — |
| Segment | Revenue | Share |
|---|---|---|
| 眼科用药 | ¥0.09B | 27.8% |
| 两性健康用药 | ¥0.09B | 27.6% |
| 其他主营业务 | ¥0.07B | 22.8% |
| 肠胃用药 | ¥0.07B | 21.8% |
| 其他(补充) | ¥0.00B | 0.1% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.14B | 43.9% |
| R&D | ¥0.03B | 9.5% |
| SG&A | ¥0.16B | 48.7% |
| Tax & other | ¥-0.01B | -4.0% |
| Item | Amount |
|---|---|
| Total assets | ¥2.54B |
| Total liabilities | ¥0.82B |
| Shareholders' equity | ¥1.72B |
| Equity / assets | 67.6% |
| Operating cash flow | ¥0.10B |
| Capital expenditure | ¥0.05B |
| Free cash flow | ¥0.04B |
| Cash conversion (OCF / net income) | -1364% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
华新科技 ・ 宇邦新材 ・ 华厦眼科 ・ 铭利达 ・ 汉仪股份 ・ 英华特 ・ 瑞晨环保 ・ 汉朔科技 ・ 嘉曼服饰 ・ 新天地 ・ 快可电子 ・ 金道科技
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies